Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence

Vasc Med. 2021 Feb;26(1):53-55. doi: 10.1177/1358863X20974452. Epub 2020 Dec 29.

Authors

Alexandra Kilian¹, Marianne S Clancy², Scott Olitsky², James R Gossage³, Marie E Faughnan^{1

4}

Affiliations

¹ Department of Medicine, Division of Respirology, Toronto HHT Centre, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
² Cure HHT, Monkton, MD, USA.
³ Department of Medicine, Division of Pulmonary and Critical Care Medicine, Augusta University, Augusta, GA, USA.
⁴ Li Ka Shing Knowledge Institute and the Keenan Research Centre for Biomedical Science, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.

No abstract available

Keywords: arteriovenous malformation; cerebral; hereditary hemorrhagic telangiectasia (HHT); pulmonary; rare diseases; screening.

MeSH terms

Central Nervous System Vascular Malformations*
Humans
Lung
North America / epidemiology
Standard of Care
Telangiectasia, Hereditary Hemorrhagic* / diagnosis
Telangiectasia, Hereditary Hemorrhagic* / therapy